North America Antibiotics Market By Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors), By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Antibiotics Market
The North America Antibiotics Market would witness market growth of 4.6% CAGR during the forecast period (2020-2026). Antibiotics are the combination of medicines that are used to cure an infection caused by germs-bacteria and some parasites, by restricting the growth of microorganisms or destroying them. These antibiotics are also called antibacterial or antimicrobials. With the discovery of the antibiotic penicillin in 1920, many antibiotic compounds have been utilized to cure various bacterial infections. Growing incidents of chronic and infectious diseases in the world and the effectiveness of antibiotics to cure a broad spectrum of bacterial infections have resulted in the swift growth of the antibiotics market.
The development of unique approaches for advanced antibiotics for curing bacterial infections and numerous clinical trials drives the global antibiotics market. Moreover, the rising rates of infectious diseases like pneumonia, tuberculosis, HIV/AIDS, and malaria will boost the market. Following this, the increasing gap in the demand and supply of antibiotics also propel the market growth. Huge investments in research and development by biotech companies are estimated to increase the global antibiotics market.
Furthermore, favorable government regulations like the Generating Antibiotics Incentives Now (GAIN) Act provide a push to research and development processes, offering various opportunities for key companies. Although, the indiscriminate and sustained utilization of antibiotics in the last few years has helped in the development of antibiotic-resistant bacteria and pathogens. There are some infections like pneumonia; gonorrhea and tuberculosis that were initially susceptible to antibiotics have become resistant to these drugs. However, the market is estimated to observe remarkable growth because of the development of advanced molecules and novel combination therapies to cure antibiotic-resistant microbial infections.
Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
Scope of the Study
Market Segments Covered in the Report:
By Action Mechanism
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors,
- Mycolic Acid Inhibitors
By Drug Class
- Rest of North America
- GlaxoSmithKline PLC (GSK)
- Johnson and Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free